Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2021 - 2024)

Aligos Therapeutics (ALGS) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $26.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Non-Current Liabilities fell 16.17% year-over-year to $26.7 million, compared with a TTM value of $26.7 million through Dec 2024, down 16.17%, and an annual FY2024 reading of $26.7 million, down 16.17% over the prior year.
  • Total Non-Current Liabilities was $26.7 million for Q4 2024 at Aligos Therapeutics, roughly flat from $26.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $57.4 million in Q1 2022 and bottomed at $26.1 million in Q1 2024.
  • Average Total Non-Current Liabilities over 4 years is $38.7 million, with a median of $40.5 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 47.11% in 2022, then decreased 16.17% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $50.5 million in 2021, then dropped by 16.99% to $41.9 million in 2022, then decreased by 24.02% to $31.9 million in 2023, then fell by 16.17% to $26.7 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for ALGS at $26.7 million in Q4 2024, $26.7 million in Q3 2024, and $30.1 million in Q2 2024.